Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Primary Antiphospholipid Syndrome
NCT06747312Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belimumab in antiphospholipid syndrome (APS) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Level of antiphospholipid antibody titers at 18 months. Started Apr 2024; status: recruiting.
02
Drugs
belimumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT06747312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747312.